Updates are available Correction dated 2023-10-28

Article History

Received: 29 May 2023

Accepted: 6 September 2023

First Online: 3 October 2023

Change Date: 28 October 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10147-023-02427-6

Declarations

:

: Tomohisa Baba received lecture and advisor fees from Daiichi Sankyo Co., Ltd., related to the submitted work. Masahiko Kusumoto received lecture and advisor fees from Daiichi Sankyo Co., Ltd., related to the submitted work; lecture fess from AstraZeneca K.K., outside the submitted work; and a research grant from Canon Medical Systems Corp., outside the submitted work. Terufumi Kato received lecture and advisor fees from Daiichi Sankyo Co., Ltd., related to the submitted work; lecture fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., and Merck Biopharma, outside the submitted work; and research funds from AbbVie G.K., Amgen Inc., AstraZeneca K.K., BeiGene Ltd., BluePrint, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Haihe, Merck KgaA, MSD K.K., Novartis Pharma K.K., Pfizer Japan Inc., Regeneron, Takeda Pharmaceutical Co., Ltd., and TurningPoint, outside the submitted work. Yasuyuki Kurihara, Shinichi Sasaki, Katsunori Oikado, Yoshinobu Saito, Masahiro Endo, and Kazuyoshi Kuwano received lecture and advisor fees from Daiichi Sankyo Co., Ltd., related to the submitted work. Yutaka Fujiwara received advisor fees from Daiichi Sankyo Co., Ltd., related to the submitted work; lecture fees from AstraZeneca K.K., and advisor fees from Ono Pharmaceutical Co., Ltd., outside the submitted work; and clinical trial funds from Amgen Inc., AnHeart Therapeutics Inc., and Bristol-Myers Squibb K.K., outside the submitted work. Hirotsugu Kenmotsu received lecture and advisor fees from Daiichi Sankyo Co., Ltd., related to the submitted work; lecture fees from Amgen Inc., AstraZeneca K.K., Bayer Yakuhin, Ltd., Nippon Boehringer Ingelheim Co., Ltd., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., Merk Ltd., MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd., outside the submitted work; research grants from Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Eli Lilly Japan K.K., AstraZeneca K.K., and Loxo Oncology, Inc., outside the submitted work. Masafumi Sata received advisor fees from Daiichi Sankyo Co., Ltd., related to the submitted work, and research funds from Nippon Boehringer Ingelheim Co., Ltd., outside the submitted work. Toshimi Takano received lecture and advisor fees from Daiichi Sankyo Co., Ltd., related to the submitted work, and lecture fees from Chugai Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K., outside the submitted work. Ken Kato received lecture and advisor fees from Daiichi Sankyo Co., Ltd., related to the submitted work; lecture fees from Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Eli Lilly Japan K.K., Merck & Co., Inc., outside the submitted work; and research funds from Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., AstraZeneca K.K., Bayer Yakuhin, Ltd., Taiho Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Janssen Pharmaceutical K.K., Merck Biopharma Co., Ltd., and Merck & Co., Inc., outside the submitted work. Koji Hirata, Tomomi Katagiri, and Hanako Saito are employees and stock owner of Daiichi Sankyo Co., Ltd.

: Although not mandatory, the post-marketing all-case surveillance protocol was approved by the institutional review board or ethics committee at the participating sites per each site’s requirements. Written informed consent from patients, although not mandatory, was obtained. This post-marketing all-case surveillance was registered under the identifiers jRCT1080225197 (breast cancer survey) and jRCT2001200001 (gastric cancer survey).